Nov 12, 2018 - Merck's (MRK) Keytruda gains FDA approval for hepatocellular carcinoma (HCC) in patients previously treated with sorafenib.
Oct 30, 2018 - INCY earnings call for the period ending September 30, 2018.
Oct 30, 2018 -
Oct 24, 2018 - Earnings releases and key data-read outs were the key developments in the biotech sector last week.
Sep 29, 2018 - A disappointing decision could mean one fewer competitor for these biotech companies.
Sep 13, 2018 - Merck's (MRK) sBLA to include overall survival data from a key lung cancer study on Keytruda's label gets FDA's priority review. If approved, it will expand the eligible patient population.
Sep 12, 2018 - Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.
Sep 12, 2018 - Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.
Sep 11, 2018 - Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting.
Sep 05, 2018 - Merck's (MRK) sBLA for Keytruda to expand its label for a rare form of skin cancer gets priority review from FDA.